E 5826

Drug Profile

E 5826

Latest Information Update: 05 Jan 2004

Price : $50

At a glance

  • Originator Esteve
  • Developer DevCo Pharmaceuticals; Esteve
  • Class Antipsychotics
  • Mechanism of Action Serotonin receptor antagonists; Serotonin uptake inhibitors; Sigma receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 05 Jan 2004 No development reported - Preclinical for Schizophrenia in Spain (unspecified route)
  • 05 Jan 2004 No development reported - Phase-II for Schizophrenia in United Kingdom (unspecified route)
  • 26 Jun 2001 Phase-II clinical trials for Schizophrenia in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top